Triamcinolone

Pharmacologic Category

Corticosteroid, Systemic

Dosing: Adult

Note: Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually.

Dermatoses (steroid-responsive): Acetonide (Kenalog-10): 1 mg Intralesional: Initial dose varies depending on the specific disease and lesion being treated; may be repeated at weekly or less frequent intervals; multiple sites may be injected if they are ≥1 cm apart.

Gout, acute flares (alternative agent): Note: Do not use if there is suspicion for infectious involvement.

Patients whose gout flare is limited to 1 to 2 joints and/or who are unable to take oral medications: Intra-articular: Acetonide (Kenalog-10): Larger joint (eg, knee): 40 mg; Medium joint (eg, wrist, ankle, elbow): 30 mg; Small joint: 10 mg (Becker 2020).

Patients with polyarticular involvement unable to take oral medications and who are not candidates for intra-articular injection: IM: Acetonide (Kenalog-40): Initial: 40 to 60 mg as a single dose; may repeat once or twice at ≥48-hour intervals if benefit fades or there is no flare resolution (Alloway 1993; Becker 2020; Siegal 1994).

Inflammatory/allergic conditions/other steroid-responsive systemic conditions: Acetonide (Kenalog-40): IM: Initial: 60 mg; adjust dose to a range of 40 to 80 mg. For patients with hay fever or pollen asthma who are not responding to pollen administration and other conventional therapy, a single injection of 40 to 100 mg per season may be given.

Multiple sclerosis (acute exacerbation):

Note: Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).

Acetonide (Kenalog-40): IM: 160 mg daily for 1 week, followed by 64 mg every other day for 1 month.

Rheumatic conditions (excluding acute gout flares):

Intra-articular (or similar injection as designated): Note: Dose ranges per manufacturer's labeling. Specific dose is determined based upon joint size, severity of inflammation, amount of articular fluid present, and clinician judgment.

Acetonide: Intra-articular, intrabursal, tendon sheaths: Initial: Smaller joints: 2.5 to 5 mg, larger joints: 5 to 15 mg; may require up to 10 mg for small joints and up to 40 mg for large joints; maximum dose/treatment (several joints at one time): 80 mg.

Zilretta only: Intra-articular: Single dose: 32 mg. Note: For osteoarthritis (OA) pain of the knee only (use for OA pain of shoulder and hip have not been evaluated); use is not suitable for small joints (eg, hand). Safety and efficacy of repeat administration has not been studied.

Hexacetonide [Canadian product]: Intra-articular: Average dose: 2 to 20 mg; smaller joints (interphalangeal, metacarpophalangeal): 2 to 6 mg; large joints (knee, hip, shoulder): 10 to 20 mg. Frequency of injection into a single joint is every 3 to 4 weeks as necessary; to avoid possible joint destruction use as infrequently as possible.

IM: Acetonide (Kenalog-40): Initial: 60 mg; range: 2.5 to 100 mg/day.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Pediatric

Note: Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually.

General dosing, treatment of inflammatory and allergic conditions:

Children and Adolescents: Triamcinolone acetonide (Kenalog-40): IM: Initial: 0.11 to 1.6 mg/kg/day (or 3.2 to 48 mg/m2/day) in 3 to 4 divided doses.

Juvenile idiopathic arthritis (JIA), other rheumatic conditions:

Triamcinolone acetonide (Kenalog-10, -40, or -80): Children and Adolescents: Intra-articular: Initial: Smaller joints: 2.5 to 5 mg, larger joints: 5 to 15 mg; maximum dose/treatment (several joints at one time): 20 to 80 mg.

Canadian labeling: Triamcinolone hexacetonide (Canadian product; not available in the US):

Children 3 to 12 years: Intra-articular:

Large joints (knees, hips, shoulders): 1 mg/kg/dose.

Small joints (ankles, wrists, elbows): 0.5 mg/kg/dose.

Hands and feet:

Metacarpophalangeal/metatarsophalangeal joints: 1 to 2 mg/dose.

Proximal interphalangeal joints: 0.6 to 1 mg/dose.

Adolescents: Intra-articular: Average dose: 2 to 20 mg/dose every 3 to 4 weeks as necessary; to avoid possible joint destruction use as infrequently as possible. Dose dependent upon degree of inflammation and joint involved:

Large joints (knee, hip, shoulder): 10 to 20 mg/dose.

Smaller joints (interphalangeal, metacarpophalangeal): 2 to 6 mg/dose.

Infantile hemangioma, severe: Limited data available: Infants and Children ≤49 months: Triamcinolone acetonide (Kenalog-10 or -40): Intralesional: Dosage dependent upon size of lesion: Commonly reported: 1 to 2 mg/kg/dose administered in divided doses along the lesion perimeter ~monthly (4 to 5 weeks most frequently reported interval); a maximum dose up to 30 mg/dose has been used; others have reported: 1 to 30 mg of the 10 mg/mL acetonide injection divided into multiple injections along the lesion; has also been used in combination with betamethasone intralesional injections (AAP [Darrow 2015]; Chen 2000; Maguiness 2012; Pandey 2009; Prasetyono 2011). From the largest reported experience (n=1,514; age range: 1 to 49 months), triamcinolone (1 to 2 mg/kg once every month) alone or in combination with oral corticosteroid (if no response after 6 injections of monotherapy) showed lesion size decrease of 50% or more in 90.3% of infants (age <1 year) and 80% in those >1 year (Pandey 2009). Another trial (n=155; age range at first injection: 2 to 12 months) which used 1 to 30 mg of a 10 mg/mL concentration administered approximately once monthly (mean interval: 5 weeks) for 3 to 6 months showed lesion size decreased by at least 50% in 85% of the patients (Chen 2000).

Dermatoses (steroid-responsive, including contact/atopic dermatitis):

Triamcinolone acetonide (Kenalog-10): Intradermal: Adolescents: Up to 1 mg per injection site and may be repeated 1 or more times weekly; multiple sites may be injected if they are 1 cm or more apart, not to exceed 30 mg.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Calculations

• Corticosteroid Conversion (Glucocorticoid Effect)

Use: Labeled Indications

Intra-articular or soft tissue administration (triamcinolone hexacetonide [Canadian product]): Symptomatic treatment of subacute and chronic inflammatory joint diseases including: synovitis, tendinitis, bursitis, epicondylitis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), osteoarthritis, or post-traumatic arthritis.

Intralesional administration (triamcinolone acetonide [Kenalog-10 only]): Alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum; cystic tumors of an aponeurosis or tendon (ganglia).

Intramuscular administration (triamcinolone acetonide [Kenalog-40] only):

Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, or transfusion reactions.

Dermatologic diseases: Atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, exfoliative erythroderma, mycosis fungoides, pemphigus, or severe erythema multiforme (Stevens-Johnson syndrome).

Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice), congenital adrenal hyperplasia, hypercalcemia associated with cancer, or nonsuppurative thyroiditis.

GI diseases: To tide the patient over a critical period of disease in Crohn disease or ulcerative colitis.

Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, select cases of secondary thrombocytopenia.

Neoplastic diseases: Palliative management of leukemias and lymphomas.

Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Note: Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).

Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that is caused by lupus erythematosus.

Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

Rheumatic disorders: As adjunctive therapy for short-term administration in acute gout flares; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; RA, including juvenile RA; treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Miscellaneous: Trichinosis with neurologic or myocardial involvement; tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.

* See Uses in AHFS Essentials for additional information.

Class and Related Monographs

Glucocorticoids

Comparative Efficacy

• TRIAMCINOLONE ACETONIDE INJECTABLE SUSPENSION

Clinical Practice Guidelines

Gout:

3e Initiative, Guidelines for the Management of Gout, 2014

American College of Rheumatology (ACR), Guidelines for the Management of Hyperuricemia, 2012

BSR/BHPR, Guideline for the Management of Gout, 2007

Juvenile Idiopathic Arthritis:

American College of Rheumatology, “2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis,” 2013

Administration: IM

Shake well before use to ensure suspension is uniform. Inspect visually to ensure no clumping; administer immediately after withdrawal so settling does not occur in the syringe. Do not administer any product IV or via the epidural or intrathecal route

Kenalog-40 injection: For IM administration. When administered IM, inject deep into the gluteal muscle using a minimum needle length of 11/2 inches. Obese patients may require a longer needle. Alternate sites for subsequent injections. Avoid IM injections into deltoid area.

Administration: Other

Shake well before use to ensure suspension is uniform. Inspect visually to ensure no clumping; administer immediately after withdrawal so settling does not occur in the syringe. Do not administer any product IV or via the epidural or intrathecal route.

Acetonide:

Kenalog-10 injection: For intra-articular or intralesional administration only. When administered intralesionally, inject directly into the lesion (ie, intradermally or subcutaneously). One mL syringes with a 23- to 25-gauge needle are preferable for intralesional injections.

Kenalog-40 injection: For intra-articular or soft tissue administration.

Zilretta injection: For intra-articular administration only; do not administer IV, IM, SubQ, intrathecally, intraocularly, intradermally, or via epidural. Prepare suspension only using the diluent supplied in the kit (refer to manufacturer labeling for preparation instructions and administration techniques). Promptly inject after preparation. If needed, may store suspension in the vial ≤4 hours at ambient conditions; gently swirl vial to resuspend any settled microspheres prior to preparing syringe for injection. Aspiration of synovial fluid may be performed based on clinical judgment prior to administration.

Hexacetonide [Canadian product]: For intra-articular and soft tissue administration only; use a 25- or 26-gauge needle.

Administration: Pediatric

Parenteral: Shake well before use to ensure suspension is uniform. Inspect visually to ensure no clumping; administer immediately after withdrawal so settling does not occur in the syringe. Do not administer any product IV or via the epidural or intrathecal route.

Acetonide:

Kenalog-10 injection: For intra-articular or intralesional administration only. When administered intralesionally, inject directly into the lesion (ie, intradermally or subcutaneously). Tuberculin syringes with a 23- to 25-gauge needle are preferable for intralesional injections. For infantile hemangioma, 27- and 30-gauge needles have been used (Chen 2000; Prasetyono 2011).

Kenalog-40, -80 injection: For intra-articular, soft tissue or IM administration. When administered IM, inject deep into the gluteal muscle using a minimum needle length of 11/2 inches for adults. Obese patients may require a longer needle. Alternate sites for subsequent injections. Avoid IM injections into deltoid area.

Hexacetonide [Canadian product, not available in US]: For intra-articular and soft tissue administration only; use a 25- or 26-gauge needle.

Dietary Considerations

Ensure adequate intake of calcium and vitamins (or consider supplementation) in patients on medium-to-high doses of systemic corticosteroids.

Storage/Stability

Acetonide injectable suspension: Store at 20°C to 25°C (68°F to 77°F); avoid freezing. Protect from light.

Zilretta only: Store kit at 2°C to 8°C (36°F to 46°F). Do not freeze. If refrigeration is unavailable, may store unopened kit at ≤77°F (25°C) for ≤ 6 weeks. Do not store >77°F (25°C). May store reconstituted suspension in the vial ≤4 hours at ambient conditions.

Hexacetonide injectable suspension [Canadian product]: Store at 15°C to 30°C (59°F to 86°F).

Preparation for Administration: Adult

Hexacetonide injectable suspension [Canadian product]: Avoid diluents containing parabens, phenol, or other preservatives (may cause flocculation). Solutions for intra-articular use may be diluted with lidocaine 1% or 2% (or similar local anesthetic).

Preparation for Administration: Pediatric

Suspension for intralesional (5 mg/mL) administration may be diluted with D5NS, D10NS, NS, or SWFI to a 1:1, 1:2, or 1:4 concentration. Solutions for intra-articular administration may be diluted with lidocaine 1% or 2%. Hexacetonide injectable suspension (Canadian product): Shake well before use to ensure suspension is uniform. Inspect visually to ensure no clumping; avoid diluents containing parabens, phenol, or other preservatives (may cause flocculation).

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat arthritis of the knee.

• It is used for many health problems like allergy signs, asthma, adrenal gland problems, blood problems, skin rashes, or swelling problems.

• This is not a list of all health problems that this drug may be used for. Talk with the doctor.

Frequently reported side effects of this drug

• Nausea

• Vomiting

• Trouble sleeping

• Agitation

• Hair thinning

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Infection

• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit

• Cushing syndrome like weight gain in upper back or abdomen; moon face; severe headache; or slow healing

• Adrenal gland problems like severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss

• Low potassium like muscle pain or weakness, muscle cramps, or an abnormal heartbeat

• Severe abdominal pain

• Loss of strength and energy

• Irritability

• Tremors

• Fast heartbeat

• Confusion

• Sweating a lot

• Severe headache

• Severe dizziness

• Passing out

• Shortness of breath

• Excessive weight gain

• Swelling of arms or legs

• Bruising

• Bleeding

• Vomiting blood

• Thrush

• Bone pain

• Joint pain

• Joint swelling

• Vision changes

• Mood changes

• Behavioral changes

• Depression

• Menstrual changes

• Seizures

• Burning or numbness feeling

• Injection site redness or swelling

• Skin changes like acne, stretch marks, slow healing, or hair growth

• Black, tarry, or bloody stools

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Other safety concerns:

Contraindications

Triamcinolone acetonide: Hypersensitivity to triamcinolone or any component of the formulation; immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (IM administration only)

Canadian labeling: Additional contraindications (not in US labeling): Systemic infections; injection into infected areas

Triamcinolone hexacetonide [Canadian product]: Hypersensitivity to triamcinolone or any component of the formulation; acute psychoses; active tuberculosis; herpes simplex keratitis; systemic mycoses; parasitosis (strongyloides infections); children <3 years of age (due to benzyl alcohol); epidural or intrathecal administration

Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving >20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections.

• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids. Cases of serious anaphylaxis, including death, have been reported with triamcinolone acetonide.

• Dermal changes: Atrophy at the injection site has been reported. Avoid IM deltoid injection; subcutaneous atrophy may occur.

• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, cause activation of latent infections, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex, cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination, and fatalities have occurred.

• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).

• Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders or when given concomitantly with neuromuscular blocking agents; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.

• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, and personality changes to severe depression and frank psychotic manifestations. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.

• Septic arthritis: May occur as a complication to intra-articular or soft tissue administration; institute appropriate antimicrobial therapy as required.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.

• Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.

• Gastrointestinal disease: Use with caution or avoid use in patients with GI diseases (diverticulosis, diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.

• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.

• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.

• Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids.

• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.

• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.

• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.

• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.

• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and renal function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).

• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.

• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997], CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002, Lucente 2000, Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate administration: Administer products only via recommended route (depending on product used). Do not administer any triamcinolone product via the intrathecal route; serious adverse events, including fatalities, have been reported following intrathecal administration of corticosteroids.

• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.

• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.

• Intra-articular injection: May result in damage to joint tissues. Avoid injection into an infected site; injection into a previously infected joint is not usually recommended. Injection into unstable joints is generally not recommended. Examine any joint fluid present to exclude a septic process.

• Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Because of the risk of adverse effects, corticosteroids should be used cautiously in the elderly, in the smallest possible dose, and for the shortest possible time.

Warnings: Additional Pediatric Considerations

Adrenal suppression with failure to thrive has been reported in infants and young children receiving intralesional corticosteroid injections for the treatment of infantile hemangioma; failure to gain weight may persist until HPA axis recovers; time to recovery of adrenal function may be prolonged (mean: 19.5 weeks; range 4 to 65 weeks) (DeBoer 2008; Morkane 2011). May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with >4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). Tissue atrophy at the site of IM injection has been reported; avoid intramuscular injections into the deltoid area. Cutaneous atrophy was reported in 2.5% of pediatric patients when given intra-articularly (Bloom 2011). Prevention of periarticular subcutaneous atrophy via injecting small amounts of saline into the joint and applying pressure following the injection has been recommended (Hashkes 2005).

Pregnancy Considerations

Adverse events have been observed with corticosteroids in animal reproduction studies.

Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.

When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester. Intra-articular dosing may be used (Götestam Skorpen 2016; Makol 2011; Østensen 2009).

For dermatologic disorders in pregnant females, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006).

Breast-Feeding Considerations

Corticosteroids are present in breast milk.

The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production); therefore, caution should be used if administered to a breastfeeding female. A case report notes a decrease in milk production following a high-dose triamcinolone injection in a breastfeeding mother with a previously abundant milk supply (McGuire 2012).

Corticosteroids are generally considered acceptable in breastfeeding females when used in usual doses (Götestam Skorpen 2016; WHO 2002); however, monitoring of the breastfeeding infant is recommended (WHO 2002). If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfeeding infant (based on a study using prednisolone) (Bae 2012; Butler 2014; Götestam Skorpen 2016; Leachman 2006; Makol 2011; Ost 1985).

Briggs' Drugs in Pregnancy & Lactation

• Triamcinolone

Adverse Reactions

Most reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for systemic triamcinolone.

1% to 10%:

Hematologic & oncologic: Bruise (extended release: 2%)

Neuromuscular & skeletal: Joint swelling (extended release: 3%)

Respiratory: Cough (extended release: 2%), sinusitis (extended release: 2%)

Frequency not defined:

Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac failure, cardiomegaly, cerebrovascular accident, circulatory shock, edema, embolism (fat), hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (following recent myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis

Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, diaphoresis, ecchymoses, epidermal thinning, erythema of skin, exfoliation of skin, hyperpigmentation, hypertrichosis, hypopigmentation, inadvertent suppression of skin test reaction, skin atrophy, skin rash, subcutaneous atrophy, thinning hair, urticaria, xeroderma

Endocrine & metabolic: Calcinosis, decreased glucose tolerance, decreased serum potassium, diabetes mellitus, drug-induced Cushing's syndrome, fluid retention, glycosuria, growth retardation, hirsutism, impaired glucose tolerance/prediabetes, insulin resistance, menstrual disease, moon face, negative nitrogen balance, redistribution of body fat, secondary adrenocortical insufficiency, sodium retention, weight gain

Gastrointestinal: Abdominal distention, change in bowel habits, gastrointestinal hemorrhage, gastrointestinal perforation, hiccups, increased appetite, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis

Genitourinary: Bladder dysfunction, postmenopausal bleeding, spermatozoa disorder

Hematologic & oncologic: Nonthrombocytopenic purpura, petechia

Hepatic: Hepatomegaly, increased liver enzymes

Hypersensitivity: Anaphylaxis, angioedema

Infection: Increased susceptibility to infection, infection, sterile abscess

Local: Postinjection flare

Nervous system: Abnormal sensory symptoms, arachnoiditis, depression, emotional lability, euphoria, headache, idiopathic intracranial hypertension (upon discontinuation), increased intracranial pressure, insomnia, malaise, meningitis, mood changes, myasthenia, neuritis, neuropathy, paraplegia, paresthesia, personality changes, psychiatric disturbance, quadriplegia, seizure, spinal cord infarction, vertigo

Neuromuscular & skeletal: Amyotrophy, aseptic necrosis of femoral head, aseptic necrosis of humeral head, bone fracture, Charcot arthropathy, lupus erythematous-like rash, osteoporosis, rupture of tendon, steroid myopathy, vertebral compression fracture

Ophthalmic: Blindness (periocular; rare), cataract, cortical blindness, exophthalmos, glaucoma, increased intraocular pressure, papilledema

Renal: Increased urine calcium excretion

Respiratory: Pulmonary edema

Miscellaneous: Wound healing impairment

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Corticosteroid Allergy

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy

Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination

Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy

Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy

Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. Risk C: Monitor therapy

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Antihepaciviral Combination Products: May increase the serum concentration of Triamcinolone (Systemic). Risk C: Monitor therapy

Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment. Risk D: Consider therapy modification

Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel. Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity. Risk D: Consider therapy modification

Baricitinib: Immunosuppressants may enhance the immunosuppressive effect of Baricitinib. Management: Use of baricitinib in combination with potent immunosuppressants such as azathioprine or cyclosporine is not recommended. Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted. Risk D: Consider therapy modification

BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). Risk C: Monitor therapy

Cladribine: May enhance the immunosuppressive effect of Immunosuppressants. Risk X: Avoid combination

Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Risk C: Monitor therapy

Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy

Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. Risk C: Monitor therapy

Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Risk C: Monitor therapy

Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment. Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation. Risk D: Consider therapy modification

Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Echinacea: May diminish the therapeutic effect of Immunosuppressants. Management: Consider avoiding Echinacea in patients receiving therapeutic immunosuppressants. If coadministered, monitor for reduced efficacy of the immunosuppressant during concomitant use. Risk D: Consider therapy modification

Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Fexinidazole [INT]: Corticosteroids (Systemic) may enhance the arrhythmogenic effect of Fexinidazole [INT]. Risk X: Avoid combination

Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Risk D: Consider therapy modification

Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. Management: Decrease oral dexamethasone or methylprednisolone dose by 50% during coadministration with fosaprepitant/aprepitant. Reduce intravenous methylprednisolone dose by 25% during coadministration with fosaprepitant/aprepitant. Risk D: Consider therapy modification

Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Risk D: Consider therapy modification

Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic). Risk C: Monitor therapy

Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. Risk X: Avoid combination

Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy

Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification

Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination

Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination

MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment. Risk X: Avoid combination

Mitotane: May decrease the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination

Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments Risk D: Consider therapy modification

Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. Risk C: Monitor therapy

Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Management: Avoid use of immunosuppressants (including systemic corticosteroids) prior to initiation of nivolumab. Use of immunosuppressants after administration of nivolumab (eg, for immune-related toxicity) is unlikely to affect nivolumab efficacy. Risk D: Consider therapy modification

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C: Monitor therapy

Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Risk C: Monitor therapy

Ozanimod: Immunosuppressants may enhance the immunosuppressive effect of Ozanimod. Risk C: Monitor therapy

Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. Risk C: Monitor therapy

Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Risk C: Monitor therapy

Ritonavir: May enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic). Risk C: Monitor therapy

Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Management: Consider avoiding concomitant use of roflumilast and immunosuppressants as recommended by the Canadian product monograph. Inhaled or short-term corticosteroids are unlikely to be problematic. Risk D: Consider therapy modification

Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy

Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. Risk C: Monitor therapy

Siponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Risk C: Monitor therapy

Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Somatropin: Corticosteroids (Systemic) may diminish the therapeutic effect of Somatropin. Risk C: Monitor therapy

Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. Risk C: Monitor therapy

Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel. Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome). Risk D: Consider therapy modification

Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled). Risk C: Monitor therapy

Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Risk D: Consider therapy modification

Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. Risk C: Monitor therapy

Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Risk D: Consider therapy modification

Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Monitoring Parameters

Blood pressure, blood glucose, electrolytes; weight; intraocular pressure (use >6 weeks); bone mineral density; growth and development in children; HPA axis suppression

Advanced Practitioners Physical Assessment/Monitoring

Patients with diabetes should monitor glucose levels closely (corticosteroids may alter glucose levels). When used for >10 to 14 days, do not discontinue abruptly; decrease dosage incrementally.

Nursing Physical Assessment/Monitoring

Patients with diabetes should monitor glucose levels closely (corticosteroids may alter glucose levels). When used for >10 to 14 days, do not discontinue abruptly; decrease dosage incrementally.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Injection, as acetonide:

Arze-Ject-A: 40 mg/mL (3 x 1 mL) [DSC] [contains benzyl alcohol, polysorbate 80]

P-Care K40: 40 mg/mL (1 x 1 mL) [contains benzyl alcohol, polysorbate 80]

P-Care K80: 40 mg/mL (2 x 1 mL) [contains benzyl alcohol, polysorbate 80]

Pod-Care 100K: 40 mg/mL (1 x 1 mL) [contains benzyl alcohol, polysorbate 80]

Pro-C-Dure 5: 40 mg/mL (2 x 1 mL) [contains benzyl alcohol, polysorbate 80]

Pro-C-Dure 6: 40 mg/mL (3 x 1 mL) [contains benzyl alcohol, polysorbate 80]

ReadySharp Triamcinolone: 40 mg/mL (1 x 1 mL) [DSC] [contains benzyl alcohol, polysorbate 80]

Suspension, Injection, as acetonide:

Kenalog: 10 mg/mL (5 mL); 40 mg/mL (1 mL, 5 mL, 10 mL) [contains benzyl alcohol, polysorbate 80]

Kenalog-80: 80 mg/mL (1 mL, 5 mL) [contains benzyl alcohol, polysorbate 80]

Generic: 40 mg/mL (1 mL, 5 mL, 10 mL)

Suspension Reconstituted ER, Intra-articular, as acetonide:

Zilretta: 32 mg (1 ea) [contains polysorbate 80]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Suspension, Injection:

Generic: 40 mg/mL (5 mL)

Suspension, Injection, as acetonide:

Kenalog-10: 10 mg/mL (5 mL)

Kenalog-40: 40 mg/mL (1 mL, 5 mL)

Generic: 10 mg/mL (5 mL); 40 mg/mL (1 mL, 5 mL)

Suspension, Injection, as hexacetonide:

Aristospan: 20 mg/mL ([DSC])

Generic: 20 mg/mL (1 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• A01AC01
• H02AB08

Generic Available (US)

May be product dependent

Pricing: US

Kit (Pro-C-Dure 5 Injection)

2 X 40 mg/mL (per each): $600.49

Kit (Pro-C-Dure 6 Injection)

3 X 40 mg/mL (per each): $736.45

Suspension (Kenalog Injection)

10 mg/mL (per mL): $2.90

40 mg/mL (per mL): $11.40

Suspension (Kenalog-80 Injection)

80 mg/mL (per mL): $22.46

Suspension (Triamcinolone Acetonide Injection)

40 mg/mL (per mL): $9.71 - $10.20

Suspension Reconstituted ER (Zilretta Intra-articular)

32 mg (per each): $684.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

A long acting corticosteroid with minimal sodium-retaining potential. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses

Pharmacodynamics/Kinetics

Onset: Adrenal suppression: IM (acetonide): 24 to 48 hours; Intra-articular: >24 hours

Duration: Adrenal suppression: IM (acetonide): 30 to 40 days; Intra-articular: 28 to 42 days

Distribution: Vd: IV (acetonide): 99.5 L

Metabolism: Hepatic (Asare 2007)

Half-life elimination: Plasma: 300 minutes (Asare 2007)

Excretion: Urine (75% primarily); bile and feces (25%) (Asare 2007)

Dental Use

Adjunctive treatment and temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma

* See Uses in AHFS Essentials for additional information.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Ulcerative esophagitis, perioral dermatitis, atrophy of oral mucosa, burning, irritation, and oral monilia (oral inhaler).

Effects on Bleeding

No information available to require special precautions

Related Information

• Beers Criteria 2019: Potentially Inappropriate Medication Use in Older Adults ≥65 Years of Age
• Corticosteroids Systemic Equivalencies
• Stress Replacement of Corticosteroids

Index Terms

Triamcinolone Acetonide; Triamcinolone Acetonide, Parenteral; Triamcinolone Hexacetonide

FDA Approval Date

January 04, 1960

References

Abraham E, Evans T. Corticosteroids and Septic Shock [editorial]. JAMA. 2002;288(7):886-887.[PubMed 12186608]

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20(1):111-113.[PubMed 8441139]

American Academy of Orthopaedic Surgeons Clinical Practice Guidelines on the Treatment Of Osteoarthritis Of The Knee (Non-Arthroplasty). Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2008. Available at http://www.aaos.org/research/guidelines/oakguideline.pdf

Annane D, Sebille V, Charpentier C, et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock. JAMA. 2002;288(7):862-871.[PubMed 12186604]

Asare K. Diagnosis and treatment of adrenal insufficiency in the critically ill patient. Pharmacotherapy. 2007;27(11):1512-1528.[PubMed 17963461]

Bae YS, Van Voorhees AS, Hsu S, et al; National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(3):459-477.[PubMed 22018758]

Becker MA. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 16, 2020.

Bloom BJ, Alario AJ, Miller LC. Intra-articular corticosteroid therapy for juvenile idiopathic arthritis: report of an experiential cohort and literature review. Rheumatol Int. 2011;31(6):749-756.[PubMed 20155422]

Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417.[PubMed 24528912]

Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm.[PubMed 6810084]

Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm.[PubMed 6423951]

Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg. 2000;35(3):420-423.[PubMed 10726680]

Cooper MS, Stewart PM. Corticosteroid Insufficiency in Acutely Ill Patients. N Engl J Med. 2003;348(8):727-734.[PubMed 12594318]

Coursin DB, Wood KE. Corticosteroid Supplementation for Adrenal Insufficiency. JAMA. 2002;287(2):236-240.[PubMed 11779267]

Darrow DH, Greene AK, Mancini AJ, Nopper AJ; Section on Dermatology, Section on Otolaryngology–Head and Neck Surgery, and Section on Plastic Surgery. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136(4):e1060-e1104.[PubMed 26416931]

de Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study. JAMA. 2002;288(22):2859-2867.[PubMed 12472328]

DeBoer MD, Boston BA. Failure-to-thrive in an infant following injection of capillary hemangioma with triamcinolone acetonide. Clin Pediatr. 2008;47(3):296-299.[PubMed 18057161]

Frey BM, Frey FJ. Clinical Pharmacokinetics of Prednisone and Prednisolone. Clin Pharmacokinet. 1990;19(2):126-146.[PubMed 2199128]

Goedert JJ, Vitale F, Lauria C, et al. Risk Factors for Classical Kaposi's Sarcoma. J Natl Cancer Inst. 2002;94(22):1712-1718.[PubMed 12441327]

Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.[PubMed 26888948]

Gutin PH. Corticosteroid Therapy in Patients With Brain Tumors. Natl Cancer Inst Monogr. 1977;46:151-156.[PubMed 349394]

Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294(13):1671-1684.[PubMed 16204667]

Hotchkiss RS, Karl IE. The Pathophysiology and Treatment of Sepsis. N Engl J Med. 2003;348(2):138-150.[PubMed 12519925]

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Kenalog-10 (triamcinolone acetonide) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2018.

Kenalog-10 (triamcinolone acetonide) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2018.

Kenalog-10 (triamcinolone acetonide) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017.

Kenalog-40 (triamcinolone acetonide) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2019.

Kenalog-40 (triamcinolone acetonide) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017.

Kenalog-80 (triamcinolone acetonide) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2019.

Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461.[PubMed 23024029]

Kimberly RP. Glucocorticoids. Curr Opin Rheumatol. 1994;6(3):273-280.[PubMed 8060761]

Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.

Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.[PubMed 27941129]

Leachman SA, Reed BR. The Use of Dermatologic Drugs in Pregnancy and Lactation. Dermatol Clin. 2006;24(2):167-197, vi.[PubMed 16677965]

Leonard MB, "Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease," Pediatrics, 2007, 119 (Suppl 2):S166-74.[PubMed 17332238]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Lunghi L, Pavan B, Biondi C, et al. Use of Glucocorticoids in Pregnancy. Curr Pharm Des. 2010;16(32):3616-3637.[PubMed 20977425]

Maguiness SM, Frieden IJ. Management of difficult infantile haemangiomas. Arch Dis Child. 2012;97(3):266-271.[PubMed 22215816]

Makol A, Wright K, Amin S. Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management. Drugs. 2011;71(15):1973-1987.[PubMed 21985166]

McGee S, Hirschmann J. Use of Corticosteroids in Treating Infectious Diseases. Arch Intern Med. 2008;168(10):1034-1046.[PubMed 18504331]

McGuire E. Sudden Loss of Milk Supply Following High-Dose Triamcinolone (Kenacort) Injection. Breastfeed Rev. 2012;20(1):32-34.[PubMed 22724311]

Morkane C, Gregory JW, Watts P, Warner JT. Adrenal suppression following intralesional corticosteroids for periocular haemangiomas. Arch Dis Child. 2011;96:587-589.[PubMed 21321258]

National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE clinical guideline CG186. London, UK: National Institute for Health and Care Excellence; October 2014. nice.org.uk/guidance/cg186. Accessed October 7, 2016.

Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106(6):1008-1011.[PubMed 3998938]

Østensen M, Forger F. Management of RA Medications in Pregnant Patients. Nat Rev Rheumatol. 2009;5(7):382-390.[PubMed 19506586]

Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years' experience of steroids in infantile hemangioma - a developing country's perspective. J Pediatr Surg. 2009;44(4):688-694.[PubMed 19361627]

Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies. Teratology. 2000;62(6):385-392.[PubMed 11091360]

Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First Trimester Exposure to Corticosteroids and Oral Clefts. Birth Defects Res A Clin Mol Teratol. 2003;67(12):968-970.[PubMed 14745915]

Prasetyono TOH, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma. Ann Plast Surg. 2011;66:98-106.[PubMed 21042190]

Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome. Arch Dis Child. 1994;70(2):151-157.[PubMed 8129444]

Salem M, Tainsh RE Jr, Bromberg J, et al. Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem. Ann Surg. 1994;219(4):416-425.[PubMed 8161268]

Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128-2134.[PubMed 22156988]

Shelly WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21(7):1325-1327.[PubMed 7966077]

Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335.[PubMed 23868909]

Triamcinolone hexacetonide injectable suspension [product monograph]. Bolton, Ontario, Canada: Medexus Inc; December 2017.

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.[PubMed 16707532]

Zilretta (triamcinolone acetonide) [prescribing information]. Burlington, MA: Flexion Therapeutics Inc; May 2018.

Zilretta (triamcinolone acetonide) [prescribing information]. Burlington, MA: Flexion Therapeutics Inc; December 2019.

Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology. 2003;42(10):1254-1259.[PubMed 12810938]

Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford). 2004;43(10):1288-1291.[PubMed 15252213]

Brand Names: International

Acetidrona (UY); Aftab (DE); Albicort (BE); Amcinol (EG); Aristocort (BD); Aristocort A (TH); Atrinat (CL); Avcort (IN); Bluxam (ES, PT); Cenalog (UA); Cenolon (BD, LK); Cynocort (BD); Danizax (VN); Delphicort (AT); Deltrianolona (CO); Epirelefan (EG); Flamicort (ID); Forticinolone (AR); Intralon (CR, DO, GT, HN, NI, SV); Introlan (PA); Ioncort (UY); Kenacort (EG, IN, MX, NO, VE, VN); Kenacort A (AE, BE, CH, KW, LK, SA); Kenacort E (PE); Kenacort IM (PE); Kenacort Retard (FR); Kenacort T (NO); Kenacort-A (AU, ID, LU, NZ, PE); Kenacort-A I.M. (CO); Kenalog (DK, EE, GB, HR, HU, LT, LV); Kenalog-40 (BB, SG); Kilcort (ET); Konicort (ID); Ledercort (AE, IN, JO, KR); Lederlon (DE); Lederspan (AE, FI); Loncort (IN); MaQaid (JP); Maquaid (KR); Oracort (IL); Panbicort (JO); Polkortolon (UA); Rabeolone (VN); Rheudenolone (KR); Shincort (HK, MY, PH, SG, TH); Sivkort (MY); Softram (MX); Solu-Volon (AT); Sterocort (IL); Stucort (IN); T-Cort (BD); Thainocort (TH); Tracinone (KR); Tramsicort (MX); Trecilon (BD); Tri-Ject (IN); Triam (DE, KR); Triamcort (AR); TriamHEXAL (DE); Triamhexal (TR); Triamon (BD); Trica (NO); Tricort (ET); Trigon Depot (ES); Trilac (ID, PH); Trimcort (BD); Trinakor (CO); Trincort (LK); Trispan (HK); Trispane (AT); Volon A (AT); Volon A 10 (DE); Volon A 40 (DE)

Last Updated 5/4/20